CN112384210A - 苏糖酸镁组合物及其用途 - Google Patents

苏糖酸镁组合物及其用途 Download PDF

Info

Publication number
CN112384210A
CN112384210A CN201980042120.9A CN201980042120A CN112384210A CN 112384210 A CN112384210 A CN 112384210A CN 201980042120 A CN201980042120 A CN 201980042120A CN 112384210 A CN112384210 A CN 112384210A
Authority
CN
China
Prior art keywords
dosage form
magnesium
threonate
day
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980042120.9A
Other languages
English (en)
Chinese (zh)
Inventor
刘国松
毛飞
J·G·温格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocentria Inc
Original Assignee
Neurocentria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocentria Inc filed Critical Neurocentria Inc
Priority to CN202510100476.0A priority Critical patent/CN120241690A/zh
Priority to CN202510100404.6A priority patent/CN120168449A/zh
Publication of CN112384210A publication Critical patent/CN112384210A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980042120.9A 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途 Pending CN112384210A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510100476.0A CN120241690A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN202510100404.6A CN120168449A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662756P 2018-04-25 2018-04-25
US62/662,756 2018-04-25
PCT/US2019/028903 WO2019209943A1 (en) 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510100404.6A Division CN120168449A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN202510100476.0A Division CN120241690A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Publications (1)

Publication Number Publication Date
CN112384210A true CN112384210A (zh) 2021-02-19

Family

ID=68291941

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980042120.9A Pending CN112384210A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN202510100476.0A Pending CN120241690A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN202510100404.6A Pending CN120168449A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510100476.0A Pending CN120241690A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途
CN202510100404.6A Pending CN120168449A (zh) 2018-04-25 2019-04-24 苏糖酸镁组合物及其用途

Country Status (9)

Country Link
US (2) US11717501B2 (https=)
EP (1) EP3784227A4 (https=)
JP (2) JP2021522344A (https=)
KR (1) KR20210005662A (https=)
CN (3) CN112384210A (https=)
AU (2) AU2019261406A1 (https=)
BR (1) BR112020021812A2 (https=)
CA (1) CA3098360A1 (https=)
WO (1) WO2019209943A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114304610A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有苏糖酸镁的营养补充剂及其应用
CN119504413A (zh) * 2025-01-20 2025-02-25 浙江天启生化股份有限公司 一种l-苏糖酸镁合成方法及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途
MY197760A (en) 2020-06-01 2023-07-13 Celagenex Res India Pvt Ltd Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
JP7805352B2 (ja) * 2020-08-28 2026-01-23 ディーエフアイ ユーエスエー，エルエルシー Ｌ－キシロン酸からｌ－トレオン酸塩を生産する方法
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248137A1 (en) * 2007-03-22 2008-10-09 Guosong Liu Magnesium-Containing Food Compositions
CN102573496A (zh) * 2009-07-01 2012-07-11 玛格塞蒂克斯公司 缓释镁组合物及其用途
CN105326855A (zh) * 2015-10-27 2016-02-17 南京大学 易吸收复合夹层式螯合镁钙片
US20170128397A1 (en) * 2015-09-11 2017-05-11 Neurocentria, Inc. Threonate compounds and methods of use thereof
US20170258828A1 (en) * 2016-03-08 2017-09-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
CN107625776A (zh) * 2016-07-19 2018-01-26 无锡脑镁素生物医药科技有限公司 用于改善睡眠的镁组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
CN113143901A (zh) * 2007-03-22 2021-07-23 纽罗森特里亚股份有限公司 镁组合物及其用途
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
CN105326955B (zh) * 2015-11-02 2019-04-12 北京市眼科研究所 一种治疗睑缘炎的组合物及其制备方法
CN106360734A (zh) * 2016-09-28 2017-02-01 张家港威胜生物医药有限公司 一种同时具有减肥和美容作用的组合物及其制备方法与用途
WO2018200885A1 (en) * 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248137A1 (en) * 2007-03-22 2008-10-09 Guosong Liu Magnesium-Containing Food Compositions
CN102573496A (zh) * 2009-07-01 2012-07-11 玛格塞蒂克斯公司 缓释镁组合物及其用途
US20170128397A1 (en) * 2015-09-11 2017-05-11 Neurocentria, Inc. Threonate compounds and methods of use thereof
CN105326855A (zh) * 2015-10-27 2016-02-17 南京大学 易吸收复合夹层式螯合镁钙片
US20170258828A1 (en) * 2016-03-08 2017-09-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
CN107625776A (zh) * 2016-07-19 2018-01-26 无锡脑镁素生物医药科技有限公司 用于改善睡眠的镁组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
肖顺贞等主编, 北京医科大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114304610A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有苏糖酸镁的营养补充剂及其应用
CN119504413A (zh) * 2025-01-20 2025-02-25 浙江天启生化股份有限公司 一种l-苏糖酸镁合成方法及应用

Also Published As

Publication number Publication date
CN120168449A (zh) 2025-06-20
JP2021522344A (ja) 2021-08-30
EP3784227A4 (en) 2022-03-02
AU2019261406A1 (en) 2020-12-17
US20240156761A1 (en) 2024-05-16
US11717501B2 (en) 2023-08-08
KR20210005662A (ko) 2021-01-14
AU2025201393A1 (en) 2025-03-20
BR112020021812A2 (pt) 2021-02-23
WO2019209943A1 (en) 2019-10-31
CA3098360A1 (en) 2019-10-31
JP2025011238A (ja) 2025-01-23
US20190328689A1 (en) 2019-10-31
CN120241690A (zh) 2025-07-04
EP3784227A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
CN112384210A (zh) 苏糖酸镁组合物及其用途
KR880001090B1 (ko) 디피리다몰의 경구용 제형의 제조방법
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
US20120039954A1 (en) Method of treating insomnia
CN104902880B (zh) 包含氢吗啡酮和纳洛酮的药物组合物
JPH0696524B2 (ja) バルプロ酸をベ−スとした新規薬剤組成物及びその製法
CA2586392A1 (en) A method for alleviating signs and symptoms of spasticity
EP1814529B1 (en) Dosage form time-lagged of drugs for the therapy of insomnia
US20150030676A1 (en) Stablized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
AU2013229990A1 (en) Controlled-release solid dosage forms of mesalamine
JP2009502807A (ja) 薬剤含有率の高い製剤および投与量形態
CN104379138B (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
JP5013871B2 (ja) 経口徐放性医薬組成物
JP2665858B2 (ja) 持効性塩酸オキシブチニン製剤
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
EP1945188A2 (en) Levodopa compositions
KR20240137366A (ko) 중탄산나트륨을 포함하는 운동수행능력 개선용 또는 위장관 장해 개선용 장용성 제제
CN121910679A (zh) 一种包含速释递送组合物和缓释递送组合物的组合及其制备方法和用途
JP2011068614A (ja) ビタミン製剤
JP2007031366A (ja) 放出制御製剤
WO2007010508A2 (en) Controlled release compositions of metaxalone
HK1107282B (en) Dosage form time-lagged of drugs for the therapy of insomnia
JP2009256237A (ja) 固形製剤
JP2013040161A (ja) 粒子製剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210219

RJ01 Rejection of invention patent application after publication